Author - Administrator

Lunatus Company Iftar

Marking the celebrations during the Holy Month of Ramadan, Lunatus held an iftar for the company employees on June 8th this year. The iftar, held at the Kempinski Hotel Palm Jumeirah, saw the employees get together to break their fast, and share personal moments.Lunatus sees these events as an...

BioQ Pharma and Lunatus Add a Third Infusion Pharmaceutical to Existing Commercial Agreement Covering Arabian Gulf and Middle East

BioQ Pharma Incorporated, a specialty pharmaceutical company, and Lunatus, a company focused on building and developing profitable pharmaceutical brands in the Arabian Gulf and Middle East markets, have announced the addition of a third, ready-to-use, infusible pharmaceutical product to their existing strategic distribution, supply, and commercial agreement. Adding this third...

Epipen Team Meeting

Lunatus collaborated with Allergy Network Dubai (AND) and Dr Michael Loubser for an internal training session on food allergies and the potentially life-saving effects of Epipen. The session was held at the Pullman Hotel in JLT, Dubai, in January, earlier this year. The training was attended by the Lunatus team,...

RSOS 2017 | LUNATUS PARTICIPATES IN 3RD RED SEA OPHTHALMOLOGY SYMPOSIUM

As the prefered partner for healthcare needs in the Middle East, Lunatus is committed to keeping up-to-date with innovations in the categories in which it operates, and participated in the 3rd Red Sea Ophthalmology Symposium (RSOS), held in Jeddah from January 5th-7th 2017 in Jeddah. With lectures, courses and workshops,...

Lunatus Partners with Nanthealth to Bring Gps Cancer™ to Oncologists and Patients in The Middle East

In December 2016, Lunatus entered into an exclusive reseller agreement with NantHealth, a leading next-generation, evidence-based, personalized healthcare company, for GPS Cancer Advanced Molecular Analysis. The molecular tests will help guide the decisions made by oncologists in the Middle East regarding a patient’s treatment strategy, including choice of standard chemotherapy....